Hepion Pharmaceuticals signs USD 500,000 secured convertible note deal with Gravitas Capital - HEPA News | RalliesHepion Pharmaceuticals signs USD 500,000 secured convertible note deal with Gravitas Capital
H
HEPA• Convertible note and warrant terms
- Hepion Pharmaceuticals entered a USD 500,000 secured convertible note purchase agreement with Gravitas Capital on Sept. 3, 2026.
- The secured convertible note carries 8% annual interest payable in kind, with maturity on Sept. 3, 2027.
- Conversion becomes available upon shareholder approval to increase authorized common shares, at USD 0.04 per share.
- Gravitas also received a warrant for 12,500,000 common shares, exercisable at USD 0.06 through Sept. 3, 2031, subject to approval.
- The note is secured by all company assets under a separate security agreement.
